National Pharmaceutical Pricing Authority

Polity & Governance glossary

Also called: NPPA · Topic: Statutory, Regulatory and Quasi-judicial Bodies · NCERT: Beyond NCERT

Meaning

The National Pharmaceutical Pricing Authority (NPPA) is India's drug-price regulator. It is an attached office of the Department of Pharmaceuticals in the Ministry of Chemicals & Fertilizers. It was set up by a government resolution on 29 August 1997, not by an Act of Parliament. It fixes and revises the ceiling prices of scheduled drugs, and it watches the prices of all other drugs under the Drugs (Prices Control) Order, 2013.

It matters because medicine prices decide whether poor patients can afford treatment. NPPA is also a clear example of an executive body (a body made by a government order, not by a law) doing regulatory work.

Explanation

How NPPA came about

  • 1970: the Bureau of Industrial Costs and Prices (BICP) was set up. It advised the government on drug costs and prices.
  • 29 Aug 1997: NPPA was created by a Government Resolution (Gazette No. 159). Drug price-fixing work moved from BICP to NPPA.
  • 2008: the Department of Pharmaceuticals (DoP) was created under the Ministry of Chemicals & Fertilizers, and NPPA was placed under it.
  • Status: it is an executive body.
  • The government made it by resolution, so the government alone can change or close it.
  • Statutory regulators like SEBI or TRAI are different, because each has its own Act.

The legal tools NPPA uses

  • Drugs (Prices Control) Order (DPCO), 2013: NPPA's main rulebook. It is issued under Section 3 of the Essential Commodities Act, 1955.
  • National Pharmaceutical Pricing Policy (NPPP), 2012: notified on 7 December 2012. It rests on three principles:
  • essentiality: control the drugs listed in the NLEM;
  • control only the prices of formulations (finished medicines);

  • market-based pricing: DPCO 2013 moved drug pricing from cost-based to market-based.

  • Penalty: anyone who breaks DPCO can be punished under Section 7 of the Essential Commodities Act.

What NPPA does (the key paras of DPCO 2013)

  • Scheduled drugs (price ceiling):
  • Medicines in the National List of Essential Medicines (NLEM) form Schedule-I of DPCO 2013.
  • NPPA fixes their ceiling prices (the highest price anyone may charge) under Paras 4 & 6.
  • The NLEM itself is made by the Health Ministry (MoHFW), on the advice of the Standing National Committee on Medicines. NLEM 2022 lists 388 medicines.

  • Ceiling prices covered 933 formulations as of 23.10.2025.

  • Yearly revision (Para 16): ceiling prices are revised every year in line with the Wholesale Price Index (WPI), on or before 1 April.

  • New drugs (Para 5): NPPA fixes the retail price of a "new drug", as defined in Para 2(1)(u). About 3,570 such prices had been fixed by 23.10.2025.
  • Non-scheduled drugs (monitoring only):
  • The company sets the price itself.
  • But the MRP cannot rise by more than 10% in 12 months.

  • These drugs are about 82% of market value. Scheduled drugs are only about 18% (FY25).

  • Extraordinary power (Para 19):

  • NPPA can fix the price of any drug, in public interest, in extraordinary circumstances.

  • Trade Margin Rationalisation (TMR) is done under this power. TMR caps the extra money that distributors and chemists earn between the company's price and the MRP.

  • Overcharging: NPPA sends recovery demands to companies that charge more than the allowed price.

  • State-level arm: Price Monitoring and Resource Units (PMRUs) work in 32 States/UTs, under the State Drugs Controllers.

Limits

  • No cost audit: DPCO uses only market data, so NPPA cannot check what a drug actually costs to make.
  • TMR is not permanent: Para 19 is an emergency power used "for a limited period". DPCO has no permanent rule for TMR.
  • Weak recovery:
  • Of ₹10,013.30 crore in overcharging demands, ₹8,526.10 crore (about 85%) was still unpaid on 30.9.2025.

  • 280 of 345 court cases had been pending for 6 to more than 20 years.

  • Staff shortage: 15 of 48 sanctioned posts are vacant.

  • Outside data: under Para 9, NPPA relies on a private data firm, Pharmarack. That data does not cover hospitals, Jan Aushadhi or e-commerce.

In the Constitution and practice

  • Legal base: NPPA is not set up by the Constitution or by any Act. It comes from a 1997 Government Resolution. Its powers come from DPCO 2013, which is issued under the Essential Commodities Act, 1955.
  • Constitutional link: drug pricing serves the Directive Principles goal of improving public health (Article 47). Class 7 NCERT describes the government as a "regulator of economic activity", and NPPA is one example.
  • Where it fits among public bodies: like NITI Aayog, NPPA is an executive body. But its work (fixing prices and recovering overcharges) is regulatory. That makes it a mixed case, like those listed in the study note.
  • Key uses of its powers:
  • 2014: Para 19 was used to cap the MRPs of 106 non-scheduled formulations (22 for diabetes, 84 for heart disease).
  • 13 Feb 2017: ceiling prices for coronary stents. 16 Aug 2017: ceiling prices for knee implants.
  • 27 Feb 2019: the TMR pilot capped trade margins at 30% on 42 non-scheduled anti-cancer drugs. NPPA later reported that 526 brands fell by about 50% on average, saving about ₹984 crore a year.
  • 1 Apr 2020: all medical devices were brought under DPCO 2013.
  • 2021: TMR was applied to 6 COVID-related devices, such as oxygen concentrators and pulse oximeters.

  • Oct 2026: TMR was extended to 137 anti-cancer drugs.

  • Parliamentary oversight: the Lok Sabha Standing Committee on Chemicals & Fertilizers (33rd Report, August 2026) reviewed NPPA:

  • it called the delay in making TMR permanent "inordinate";
  • it asked for cost-based pricing to be considered where markups are abnormally high.

Don't confuse with

  • CDSCO / Drugs & Cosmetics Act, 1940: CDSCO controls the quality and safety of medicines. NPPA controls their prices, under DPCO and the Essential Commodities Act.
  • Statutory regulators (SEBI, TRAI, FSSAI): each of these was created by its own Act, with a tribunal for appeals. NPPA was created by a resolution, so it is not statutory.
  • Ministry of Health (MoHFW): MoHFW prepares the NLEM (the list of essential medicines). NPPA sits under the Ministry of Chemicals & Fertilizers and only fixes the prices.
  • Ceiling price vs TMR: a ceiling price caps the final price of scheduled drugs. TMR caps the trade margin on non-scheduled drugs, under Para 19.

Prelims Hooks

  • NPPA was set up on 29 Aug 1997 by a Government Resolution. It is not a statutory body.
  • NPPA comes under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, not MoHFW.
  • DPCO 2013 is issued under Section 3 of the Essential Commodities Act, 1955, not the Drugs & Cosmetics Act, 1940.
  • Paras of DPCO 2013:
  • Para 16: yearly revision of ceiling prices in line with WPI;
  • Para 19: extraordinary public-interest pricing, the legal base for TMR;

  • Para 5: new-drug prices.

  • Non-scheduled drug MRPs may rise by at most 10% a year. NLEM drugs form Schedule-I of DPCO 2013.

  • The first TMR (27 Feb 2019) capped trade margins at 30% on 42 anti-cancer drugs. Coronary stents were capped on 13 Feb 2017.

Mains Points

  • Executive body doing a regulator's job:
  • NPPA has no Act behind it. The government can reshape it at will.
  • TMR rests on an emergency power (Para 19), not a permanent rule.

  • The Standing Committee wants a permanent TMR framework "within a clearly defined timeframe". The Department says it has "no set time frame". This links to the wider GS-II debate on independent, accountable regulators.

  • Affordability vs viability:

  • For TMR: about 82% of the market is non-scheduled and outside ceiling prices. TMR on costly cancer drugs saves patients money.
  • Against TMR: MSME drug makers warn that blanket margin caps could hurt rural supply. NPPA itself has allowed price rises for drugs that became unviable.

  • Middle path: WHO suggests regressive markups, where the allowed percentage falls as the price rises.

  • Enforcement reform: about 85% of overcharging demands are unrecovered and cases drag on for decades. The Committee suggests:

  • a fast-track way to settle disputes outside court;
  • a legal cell inside NPPA;
  • filling vacant posts;
  • its own price database (IPDMS 2.0);
  • public consultation on prices, because almost all comments on draft prices came from companies.

Read more